These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23071229)

  • 1. Cost, coverage, and comparative effectiveness research: the critical issues for oncology.
    Pearson SD
    J Clin Oncol; 2012 Dec; 30(34):4275-81. PubMed ID: 23071229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can CER be an effective tool for change in the development and assessment of new drugs and technologies?
    Brixner DI; Watkins JB
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S06-11. PubMed ID: 22663293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness research: moving medical oncology forward.
    Hirsch BR; Zafar SY
    Semin Radiat Oncol; 2014 Jan; 24(1):49-53. PubMed ID: 24314342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of comparative effectiveness research in cancer funding decisions in Ontario, Canada.
    Hoch JS; Hodgson DC; Earle CC
    J Clin Oncol; 2012 Dec; 30(34):4262-6. PubMed ID: 23071242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
    Sorenson C
    Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.
    Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
    Pain Physician; 2010; 13(1):E23-54. PubMed ID: 20119474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Parr AT; Hirsch JA
    Pain Physician; 2011; 14(3):E249-82. PubMed ID: 21587337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Informatics in action: lessons learned in comparative effectiveness research.
    Hirsch BR; Giffin RB; Esmail LC; Tunis SR; Abernethy AP; Murphy SB
    Cancer J; 2011; 17(4):235-8. PubMed ID: 21799331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Looking at CER from Medicare's perspective.
    Mohr P
    J Manag Care Pharm; 2012 May; 18(4 Suppl A):S5-8. PubMed ID: 22578211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness research in oncology.
    Lyman GH
    Oncologist; 2013 Jun; 18(6):752-9. PubMed ID: 23697601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness research in oncology: the promise, challenges, and opportunities.
    Chen RC
    Semin Radiat Oncol; 2014 Jan; 24(1):1-4. PubMed ID: 24314336
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of comparative effectiveness research: a practical tool.
    Schaumberg DA; McDonald L; Shah S; Stokes M; Nordstrom BL; Ramagopalan SV
    J Comp Eff Res; 2018 May; 7(5):503-515. PubMed ID: 29463115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of comparative effectiveness research in Asia, Europe, and North America.
    Patel I; Rarus R; Tan X; Lee EK; Guy J; Ahmad A; Chang J
    Indian J Pharmacol; 2015; 47(6):585-93. PubMed ID: 26729947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness research in the United States: a progress report.
    Sullivan SD; Carlson JJ; Hansen RN
    J Med Econ; 2013; 16(2):295-7. PubMed ID: 23227997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating comparative effectiveness research into Medicaid payment policy: views from medical and pharmacy directors.
    Weissman JS; Westrich K; Hargraves JL; Pearson SD; Dubois R; Emond S; Olufajo OA
    J Comp Eff Res; 2015 Mar; 4(2):79-88. PubMed ID: 25825839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.